Management of prostate cancer. Part 3: metastatic disease

References

• Ornstein D, Beiser J, Andriole G. Anaemia in men receiving combined finasteride and fluatmide therapy for advanced prostate cancer. BJU Int.83, 43–46 (1999).
   PubMed Web of Science ®Google Scholar
• Fonseca R, Rajkumar S, White W, Tefferi A, Hoagland H. Anaemia after orchiectomy. Am. J. Hematol.59, 230–233 (1998).
   PubMed Web of Science ®Google Scholar
• Strum S, McDermed J, Scholz M, Johnson H, Tisman G. Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormonal blockade. BJU Int.79, 933–941 (1997).
   Google Scholar
• Reynard J, Peters T, Gillatt D. Prostate-specific antigen and prognosis in patients with metastatic prostate cancer: a multivariate analysis of prostate cancer mortality. BJU Int.75, 507–515 (1995).
   Google Scholar
• Smith J, Lange P, Janknegt R, Abbou C, deGery A. Serum marker as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate. J. Urol.157, 1329–1334 (1997).
   PubMed Web of Science ®Google Scholar
• Kelly W, Scher H, Mazumdar M, Vlamis V, Scwartz M, Fossa S. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J. Clin. Oncol.11, 607–615 (1993).
   PubMed Web of Science ®Google Scholar
• Miller J, Ahman F, Drach G, Emerson S, Bottaccini M. The clinical usefulness of serum PSA after hormonal therapy for metastatic carcinoma of the prostate. J. Urol.147, 956–961 (1992).
   PubMedGoogle Scholar
• Bolla M, Gonzalez D, Warde P et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N. Engl. J. Med.337, 295–300 (1997).
   PubMed Web of Science ®Google Scholar
• Greenspan S, Coates P, Sereika S, Nelson J, Trump D, Resnick N. Bone loss after initiation of androgen therapy in patients with prostate cancer. J. Clin. Endocrinol. Metab.90, 6410–6417 (2005).
   PubMed Web of Science ®Google Scholar
• Immediate versus deferred treatment for advanced prostate cancer: initial results of the Medical Research Council trial. Br. J. Urol.79, 235–246 (1997).
   Google Scholar
• Sticker H. Luteinizing hormone-releasing hormone antagonist in prostate cancer. Urology58, 24–27 (2001).
   PubMedGoogle Scholar
• Goldenberg S, Bruchovsky N, Gleave M, Sullivan L, Akakura K. Intermittent androgen suppression treatment of prostate cancer: a preliminary report. Urology45, 839–844 (1995).
   PubMed Web of Science ®Google Scholar
• Eisenberger M, Blumenstein B, Crawford E et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N. Engl. J. Med.339, 1036–1042 (1998).
   PubMed Web of Science ®Google Scholar
• Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists’ Collaborative Group. Lancet355(9214), 1491–1498 (2000).
   PubMed Web of Science ®Google Scholar
• Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomized trials with 3283 deaths in 5710 patients. Prostate Cancer Trialists’ Collaborative Group. Lancet346, 265–269 (1995).
   PubMed Web of Science ®Google Scholar
• Taplin M, Bubley G, Ko Y. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res.59, 149–153 (1999).
   Google Scholar
• Kelly W, Scher H. Prostate specific antigen decline after anti-androgen withdrawal: the flutamide withdrawal syndrome. J. Urol.49, 607–609 (1993).
   Google Scholar
• Small E, Schelhammer P, Venner P. A double-blind assessment of antiandrogen withdrawal from casodex (C) or eulexin (E) therapy while continuing luteinizing hormone releasing hormone analogue (LHRL-A) therapy for patients with stage D2 prostate cancer. Proc. Am. Soc. Clin. Oncol.15, 255 (1996).
   Google Scholar
• Pienta K, Redman B, Bandekar R et al. A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer. Urology50, 401–406 (1997).
   PubMedGoogle Scholar
• Smith D, Redman B, Flaherty L, Li L, Strawderman M, Pieta K. A phase II trial of oral diethylstilbestrol as a second line hormonal agent in advanced prostate cancer. Urology52, 257–260 (1998).
   PubMed Web of Science ®Google Scholar
• Dawson N. Treatment of progressive metastatic prostate cancer. Oncology7, 7–24 (1993).
   Google Scholar
• Fuse H, Nozaki T, Fujiuchi Y, Nagakawa O, Okumwa A. Treatment with prednisolone of hormone refractory prostate cancer. Arch. Androl.52, 35–38 (2006).
   PubMedGoogle Scholar
• Benson R, Hasa S, Jones A. External beam radiotherapy for palliation of multiple sites of pain from metastatic carcinoma of the prostate. J. Urol.127, 69–71 (1981).
   Google Scholar
• Nielsen OS, Bentzen SM, Sandberg E, Gadeberg CC, Timothy AR. Randomized trial of single dose versus fractionated palliative radiotherapy of bone metastases. Radiother. Oncol.47(3), 233–240 (1998).
   PubMed Web of Science ®Google Scholar
• Hartsell WF, Scott CB, Bruner DW et al. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J. Natl Cancer Inst.97(11), 798–804 (2005).
   PubMedGoogle Scholar
• Aaron A. Treatment of metastatic adenocarcinoma of the pelvis and extremities. Am. J. Bone Joint Surg.79, 917–931 (1997).
   PubMedGoogle Scholar
• Ben-Josef E, Porter A. Radioisotopes in prostate carcinoma. Ann. Med.29, 31–35 (1997).
   PubMed Web of Science ®Google Scholar
• Porter A, McEwan A, Powe J et al. Results of a randomized phase III trial to evaluate the efficacy of strontium-89 adjuvant to local field irradiation in the management of endocrine resistant metastatic prostate cancer. Int. J. Radiat. Oncol. Biol. Phys.25, 805–813 (1993).
   PubMed Web of Science ®Google Scholar
• Oosterhof GO, Roberts JT, de Reijke TM et al. Strontium89 chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group. Eur. Urol.44(5), 519–526 (2003).
   PubMed Web of Science ®Google Scholar
• Sartor O, Reid R, Hoskin P et al. Samarium-153-lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology63, 940–945 (2004).
   PubMed Web of Science ®Google Scholar
• Saad F, Gleason G, Murray R et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone refractory metastatic prostate carcinoma. J. Natl Cancer Inst.94, 1458–1468 (2002).
   PubMed Web of Science ®Google Scholar
• Tannock I, Wit R, Berry W et al. For the TAX 327 investigators. Docetaxol plus prednisolone or mitoxantrone plus prednisolone for advanced prostate cancer. N. Engl. J. Med.351, 1502–1512 (2004).
   PubMed Web of Science ®Google Scholar
• Petrylak D, Tangen C, Hussain M. Docetaxol and estramustine compared with mitoxantrone and prednisolone for advanced refractory prostate cancer. N. Engl. J. Med.351, 1513–1520 (2004).
   PubMed Web of Science ®Google Scholar
• Tannock I, Osoba D, Stockler M et al. Chemotherapy with mitoxantrone plus prednisolone or prednisolone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J. Clin. Oncol.14, 1756–1764 (1996).
   PubMed Web of Science ®Google Scholar
• Blumenstein B, Crawford ED, Saiers JH, Stephens RL, Rivkin SE, Coltman CA Jr. Doxorubicin, mitomycin C and 5-fluorouracil in the treatment of hormone refractory adenocarcinoma of the prostate: a Southwest Oncology Group study. J. Urol.150(2 Pt 1), 411–413 (1993).
   PubMed Web of Science ®Google Scholar
• Laurie JA, Hahn RG, Therneau TM et al. Chemotherapy for hormonally refractory advanced prostate carcinoma. A comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5-fluorouracil. Cancer69(6), 1440–1444 (1992).
   PubMed Web of Science ®Google Scholar
• Casey M, Byrd W, Macdonald P. Massive amounts of immunoreactive endothelin in human seminal fluid. J. Clin. Endocrinol. Metab.74, 223–225 (1992).
   PubMed Web of Science ®Google Scholar
• Nelson J, Hedican S, George D et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat. Med.1, 944–999 (1995).
   PubMed Web of Science ®Google Scholar
• Takuwa Y, Ohue Y, Takuwa N, Yamashita K. Endothelin-1 activates phospholipase C and mobilizes Ca2+ from extra- and intracellular pools in osteoblastic cells. Am. J. Physiol.257, 797–803 (1989).
   PubMed Web of Science ®Google Scholar
• Yin J, Mohammad K, Kakonen S et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc. Natl Acad. Sci. USA100, 10954–10959 (2003).
   PubMed Web of Science ®Google Scholar
• Carducci M, Nelson J, Bowling M et al. Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics. J. Clin. Oncol.20, 2171–2180 (2002).
   PubMed Web of Science ®Google Scholar
• Trump D, Hershberger P, Bernadi R et al. Antitumor activity of calcitriol: pre-clinical and clinical studies. J. Steroid Biochem. Mol. Biol.89, 519–526 (2004).
   PubMed Web of Science ®Google Scholar
• Beer T, Eilers K, Garzotto M, Egorin M, Lowe B, Henner W. Weekly high-dose calcitriol and docetaxol in metastatic androgen-independent prostate cancer. J. Clin. Oncol.21, 123–128 (2003).
   PubMed Web of Science ®Google Scholar
• Bauer K, Dixon S, Figg W. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem. Pharmacol.55, 1827–1834 (1998).
   PubMed Web of Science ®Google Scholar
• Figg W, Dahut W, Duray P et al. A randomized phase II trial of thalidomide, an antiangiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin. Cancer Res.7, 1888–1893 (2001).
   PubMed Web of Science ®Google Scholar
• Dahut W, Gulley J, Arlen P et al. Randomized phase II trial of docetaxol plus thalidomide in androgen-independent prostate cancer. J. Clin. Oncol.22, 2532–2539 (2004).
   PubMed Web of Science ®Google Scholar
• Horne M, Figg W, Arlen P et al. Increased frequency of venous thromboembolism with the combination of docetaxol and thalidomide in patients with metastatic androgen-independent prostate cancer. Pharmacotherapy23, 315–318 (2003).
   PubMed Web of Science ®Google Scholar
• Sternberg C, Whelan P, Hetherington J et al. Phase III trial of satraplatin, an oral platinum plus prednisolone vs. prednisolone alone in patients with hormone-refractory prostate cancer. Oncology68, 2–9 (2005).
   PubMed Web of Science ®Google Scholar
• Hussain T, Tangen C, Lara P, Vaishampayan U et al. Ixabepilone is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a SouthWest Oncolgy Group trial S0111. J. Clin. Oncol.23, 8724–8729 (2005).
   PubMed Web of Science ®Google Scholar
• Eaton J, Perry M, Nicholson S et al. Allogenic whole-cell vaccine: a phase I/II study in men with hormone refractory prostate cancer. BJU Int.89, 19–26 (2002).
   PubMedGoogle Scholar
• Small E, Fratesi P, Resse D. Immunotherapy of hormone-refractory prostate cancer with antigen loaded dendritic cells. J. Clin. Oncol.18, 3894–3903 (2000).
   PubMed Web of Science ®Google Scholar
• Steiner M. Review of peptide growth factors in benign prostatic hyperplasia and urological malignancies. J. Urol.153, 1085–1096 (1995).
   PubMed Web of Science ®Google Scholar
• Blades R, Keating P, McWilliam L, George N, Stern P. Loss of HLA class I expression in prostate cancer: implications for immunotherapy. Urology46, 681–686 (1995).
   PubMed Web of Science ®Google Scholar
• Healy C, Simons J, Carducci M et al. Impaired expression and function of signal-transducing ζ-chains in peripheral T cells and natural killer cells in pateints with prostate cancer. Cytometry32, 109–119 (1998).
   PubMedGoogle Scholar
• Liu H, Rajasekaran A, Moy P et al. Constitutive and antibody-induced internalization of prostate-specific antigen. Cancer Res.58, 4055–4060 (1998).
   PubMed Web of Science ®Google Scholar
• Milowsky M, Nanus D, Kostakoglu L, Vallabhajosula S, Goldsmith S, Bander N. Phase I trial of yttrium-90-labelled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J. Clin. Oncol.22, 2522–2531 (2004).
   PubMed Web of Science ®Google Scholar
• Dawson N, Cooper M, Figg W et al. Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables. Cancer76, 453–462 (1995).
   PubMed Web of Science ®Google Scholar
• Kelly W, Curley T, Leibertz C, Dnistrian A, Schwartz M, Scher H. Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer. J. Clin. Oncol.15, 2208–2213 (1995).
   Google Scholar
• Ziada A, Bargawi A, Glode L et al. The use of transtuzumab in the treatment of hormone refractory prostate cancer: phase II trial. Prostate61, 332–337 (2004).
   PubMedGoogle Scholar
• Hueman M, Dehqanzada Z, Novak Tet al. Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific recurrence in high-risk prostate cancer patients. Clin. Cancer Res.11, 7470–7479 (2005).
   PubMed Web of Science ®Google Scholar
• Lorusso P. Phase I studies of ZD1839 in patients with common solid tumours. Semin. Oncol.30, 21–29 (2003).
   PubMed Web of Science ®Google Scholar
• Tiffany N, Wersinger E, Garzotto M, Beer T. Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer. Urology63, 934–939 (2004).
   PubMed Web of Science ®Google Scholar
• Ye D, Mendelsohn J, Fan Z. Androgen and epidermal growth factor down-regulate cyclin-dependent kinase inhibitor p27Kip1 and costimulate proliferation of MDA Pca 2a and MDA Pca 2b prostate cancer cells. Clin. Cancer Res.5, 2171–2177 (1999).
   PubMed Web of Science ®Google Scholar
• Trump D, Canil CM, Moore MJ et al. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. Urol. Oncol.23, 378–379 (2005).
   Google Scholar
• Festuccia C, Gravina G, Angelucci A et al. Additive antitumour effects of the epidermal growth factor receptor tyrosine kinase inhibiotr, gefitinib (Iressa) and the nonsteroidal antiandrogen, bicalutamide (Casodex) in prostate cancer cells in vitro. Int. J. Cancer115, 630–640 (2005).
   PubMedGoogle Scholar